Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2902 DNA Methylation Analysis of the PDX1 Gene Can Be Used for PNET Subtyping and Has a Possible Prognostic Value

Introduction: Estimating prognosis of pancreatic neuroendocrine tumor (PNET) patients remains challenging. Mutation status of DAXX/ATRX/MEN1, histone modification patterns and immunohistochemistry for relevant transcription factors, including PDX1, were recently used to perform subtyping and distinguished two main types, A and B. These subtypes are linked to cell-of-origin and associated with clinical outcome.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Boons G, Vandamme T, Ibrahim J, Schepers A, Roeyen G,

Keywords: Pancreatic Neuroendocrine Tumor, DNA Methylation, Prognostic Biomarker,

#2065 Sunitinib in Patients with Pre-Treated Pancreatic Neuroendocrine Tumors: A Real-World Study

Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Rinzivillo M

Authors: Rinzivillo M, Gritti S, Pusceddu S, Spallanzani A, Ibrahim T,

Keywords: Sunitinib, neuroendocrine tumors, pancreas, progressive disease, target therapy,

#2015 Single-Institutional Review of Non-Pancreatic GI Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) most commonly occur in the digestive tract with an incidence of 3.56 per 100,000 with 94% of those being non pancreatic.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: el chami a

Authors: El Chami A, El Halabi I, Charaffedine M, Temraz S, Mukherji D,

Keywords: neuroendocrine tumor, gastrointestinal, location, prognosis,

#1368 Everolimus in Pancreatic Neuroendocrine Carcinomas G3

Introduction: Neuroendocrine Carcinomas (NEC) G3 are heterogeneous diseases with different behaviors, basing on tumor morphology and Ki67 value. Platinum-based chemotherapy is considered the standard treatment in these pts. However, tumors with well-moderately differentiated morphology (NET G3), with Ki67 < 55% may be considered a separate entity in terms of prognosis and therapeutic options

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Panzuto F

Authors: Panzuto F, Rinzivillo M, Spada F, Antonuzzo L, Ibrahim T,

Keywords: Neuroendocrine carcinoma, everolimus,

#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis

Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: IBRAHIM T

Authors: Bongiovanni A, Riva N, Monti M, Ianniello A, Pieri F,

Keywords: GEP-NEC,chemotherapy,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.